<a href="https://laohu8.com/S/BGLC">BioNexus Gene Lab Corp.</a> Acquires 15% Stake in Fidelion Diagnostics
BioNexus Gene Lab Corp. has completed a strategic equity investment in Fidelion Diagnostics Pte. Ltd., acquiring a 15% minority stake through a non-cash share swap. In return, Fidelion now holds approximately 16.6% of BioNexus Gene Lab Corp.'s issued and outstanding stock, aligning the interests of both companies. As part of the agreement, BioNexus Gene Lab Corp. also secured exclusive commercial rights to the VitaGuard™ Tumor-Naïve Minimal Residual Disease (MRD) liquid biopsy platform for Southeast Asia via a licensing agreement, with the license fee payable over 24 monthly installments. The deal is designed to preserve financial strength, minimize dilution, and support BioNexus Gene Lab Corp.'s expansion in the precision oncology market.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596053-en) on December 03, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。